文献速递泌尿生殖与妇科肿瘤放疗

局部高危前列腺癌同期大分割调强放疗推量与常规分割调强放疗推量的随机试验(pHART2-RCT)

Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-11-17

这项单中心前瞻性2期随机研究纳入180例高危前列腺癌患者,随机接受中度大分割(MH,前列腺68 Gy/25次,盆腔48 Gy)或常规分割(CF,盆腔46 Gy/23次后前列腺序贯推量32 Gy/16次)放疗并联合长期雄激素剥夺治疗。两组急性≥2级胃肠及泌尿毒性无显著差异(P=.29),但MH组晚期≥3级胃肠毒性更常见(P=.01),生活质量和肿瘤学结局无显著差异。

要点

  • MH组与CF组急性≥2级胃肠和/或泌尿毒性发生率分别为37.8%与45.6%(P=.29)。
  • MH组晚期≥3级胃肠毒性较CF组更常见(P=.01)。
  • 两组生化失败、远处转移和总生存均无显著差异。

核心结论

  • 对高危局限性前列腺癌患者,前列腺及盆腔中度大分割放疗联合雄激素剥夺治疗在急性毒性、生活质量和肿瘤学疗效方面与常规分割放疗无显著差异,但MH组晚期≥3级胃肠毒性更常见。

研究设计与样本

  • 单中心、前瞻性、2期随机研究,纳入高危前列腺癌患者(cT3、前列腺特异性抗原>20 ng/mL或Gleason评分8-10),随机接受MH(前列腺68 Gy/25次,盆腔48 Gy)或CF(盆腔46 Gy/23次,前列腺序贯推量32 Gy/16次),均联合长期雄激素剥夺治疗。
  • 共入组180例,MH组90例,CF组90例,中位随访67.4个月。
  • 主要终点为≥2级急性胃肠和泌尿毒性(常见不良事件术语标准3.0版),次要终点包括晚期胃肠和泌尿毒性、生活质量和肿瘤学结局。

主要发现

  • 75例(41.7%)发生≥2级急性胃肠和/或泌尿毒性,其中MH组34例(37.8%),CF组41例(45.6%)(P=.29)。
  • 晚期≥2级胃肠毒性(P=.07)和泌尿毒性(P=.25)两组间无显著差异,但晚期≥3级胃肠毒性MH组更差(P=.01)。
  • 两组生活质量无统计学显著差异。
  • 生化失败累积发生率(P=.71)、远处转移(P=.31)和总生存(P=.46)均无统计学显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this work is to report on the results of a phase 2 randomized trial of moderately hypofractionated (MH) versus conventionally fractionated (CF) radiation therapy to the prostate with elective nodal irradiation. METHODS AND MATERIALS: This was a single-center, prospective, phase 2 randomized study. Patients with high-risk disease (cT3, prostate-specific antigen level >20 ng/mL, or Gleason score 8-10) were eligible. Patients were randomized to either MH using a simultaneous integrated boost (68 Gy in 25 fractions to prostate; 48 Gy to pelvis) or CF (46 Gy in 23 fractions with a sequential boost to the prostate of 32 Gy in 16 fractions), with long-term androgen deprivation therapy. The primary endpoint was grade ≥2 acute gastrointestinal (GI) and genitourinary (GU) toxicity (Common Terminology Criteria for Adverse Events version 3.0). Secondary endpoints included late GI and GU toxicity, quality of life, and oncologic outcomes. RESULTS: One-hundred eighty patients were enrolled; 90 were randomized to and received MH and 90 to CF. The median follow-up was 67.4 months. Seventy-five patients (41.7%) experienced a grade ≥2 acute GI and/or GU toxicity, including 34 (37.8%) in the MH and 41 (45.6%) in the CF arms, respectively (P = .29). Late grade ≥2 GI (P = .07) and GU (P = .25) toxicity was not significantly different between arms; however, late grade ≥3 GI toxicity was worse in the MH group (P = .01). There were no statistically significant quality-of-life differences between the 2 treatments. There were no statistically significant differences observed in cumulative incidence of biochemical failure (P = .71) or distant metastasis (P = .31) and overall survival (P = .46). CONCLUSIONS: MH to the prostate and pelvis with androgen deprivation therapy for men with high-risk localized prostate cancer was not significantly different than CF with regard to acute toxicity, quality of life, and oncologic efficacy. However, late grade ≥3 GI toxicity was more common in the MH arm.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Glicksman RM, Loblaw A, Morton G, et al. Randomized Trial of Concomitant Hypofractionated Intensity Modulated Radiation Therapy Boost Versus Conventionally Fractionated Intensity Modulated Radiation Therapy Boost for Localized High-Risk Prostate Cancer (pHART2-RCT). Int J Radiat Oncol Biol Phys. 2023. PMID: 37979707. doi:10.1016/j.ijrobp.2023.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。